Trending...
- New plusOne Research Finds the Orgasm Gap Is a 30-Point Chasm — and Confirms It Isn't Biology
- Who Is Dr. Deshawnda Williams?
- 2026 Version of 6-in-1 Estate and Trust Administration Software Released by The Lackner Group
WATERTOWN, Mass., June 18, 2024 ~ Remix Therapeutics, a clinical-stage biotechnology company, has recently announced the appointment of Dr. Maria Koehler as an independent director to their Board of Directors. This move comes as Remix continues to develop small molecule therapies that target RNA processing and address the underlying causes of various diseases.
According to Peter Smith, Ph.D., Co-Founder and Chief Executive Officer of Remix, Dr. Koehler's extensive industry knowledge and experience will be invaluable as the company advances its pipeline of RNA processing modulators. This includes their lead program REM-422, which is a first-in-class therapy.
Dr. Koehler brings over 20 years of experience in leading clinical and regulatory strategy operations for biotech and pharmaceutical companies focused on oncology research and development. She currently serves as the Chief Medical Officer at Repare Therapeutics, a clinical-stage precision oncology company. In addition, she has held executive and medical leadership roles at Pfizer, AstraZeneca, Bicycle Therapeutics, and GlaxoSmithKline.
More on The PennZone
Dr. Koehler's expertise also extends to academia, where she has served as the clinical director of Bone Marrow Transplantation at University Hospital in Pittsburgh and as the director of the Bone Marrow Transplant Program at St. Christopher's Hospital in Philadelphia. She is a board-certified hematology/oncology physician with an M.D. and Ph.D. from the Silesian School of Medicine in Katowice, Poland.
Currently serving as an independent director on the boards of Ikena Oncology and Abdera Therapeutics, Dr. Koehler expressed her excitement about joining Remix during this pivotal time for the company. She believes that their innovative approach to reprogramming RNA processing holds great therapeutic potential and looks forward to working with Remix leadership and fellow board members to drive this science forward.
With Dr. Koehler's appointment, Remix is poised for success as they continue to make strides in developing groundbreaking therapies that target RNA processing. The company is confident that her expertise and guidance will be instrumental in their journey towards improving the lives of patients with various diseases.
According to Peter Smith, Ph.D., Co-Founder and Chief Executive Officer of Remix, Dr. Koehler's extensive industry knowledge and experience will be invaluable as the company advances its pipeline of RNA processing modulators. This includes their lead program REM-422, which is a first-in-class therapy.
Dr. Koehler brings over 20 years of experience in leading clinical and regulatory strategy operations for biotech and pharmaceutical companies focused on oncology research and development. She currently serves as the Chief Medical Officer at Repare Therapeutics, a clinical-stage precision oncology company. In addition, she has held executive and medical leadership roles at Pfizer, AstraZeneca, Bicycle Therapeutics, and GlaxoSmithKline.
More on The PennZone
- Nayarit's Jungle Coast Redefines Luxury Travel on Mexico's Pacific Now More Accessible Than Ever
- $10 Million Annual Revenue Merger, Profitable Partner in AI Powered Specialty Automotive Sales Projected to Scale Above $200M: Stock Symbol: NWPG
- Virginia Moving Company Nearly Doubles Customer Calls in Two Weeks After Switching to CARL — the Bold New Alternative to WordPress
- JR AIR TOOLS Launches Factory-Direct Air Hydraulic Jacks for Semi Trucks & Commercial Fleets
- RAS AP Consulting Launches Vendor Master File & Payment Controls Assessment for NACHA Phase 2 Compliance
Dr. Koehler's expertise also extends to academia, where she has served as the clinical director of Bone Marrow Transplantation at University Hospital in Pittsburgh and as the director of the Bone Marrow Transplant Program at St. Christopher's Hospital in Philadelphia. She is a board-certified hematology/oncology physician with an M.D. and Ph.D. from the Silesian School of Medicine in Katowice, Poland.
Currently serving as an independent director on the boards of Ikena Oncology and Abdera Therapeutics, Dr. Koehler expressed her excitement about joining Remix during this pivotal time for the company. She believes that their innovative approach to reprogramming RNA processing holds great therapeutic potential and looks forward to working with Remix leadership and fellow board members to drive this science forward.
With Dr. Koehler's appointment, Remix is poised for success as they continue to make strides in developing groundbreaking therapies that target RNA processing. The company is confident that her expertise and guidance will be instrumental in their journey towards improving the lives of patients with various diseases.
Filed Under: Business
0 Comments
Latest on The PennZone
- MTV EMA Nominee and WOA Founder Oliver Sean Conferred Doctor of Musical Arts (DMA) Degree
- Ryan Murphy Joins Personal Injury Law Firm Feldman Shepherd
- Karen D. Gentry Announces New Book Focused on Relationships and Personal Growth
- AWARENESS TO WELLNESS: Imhotep Institute Charter High School
- Colonial Nissan Honors Serge Panchenko for 25 Years of Service
- New plusOne Research Finds the Orgasm Gap Is a 30-Point Chasm — and Confirms It Isn't Biology
- CCHR Report Links 145 Violent Incidents to Psychiatric Drug Exposure, Urges National Oversight and Action
- Best Companies Group Launches Free Best Accounting Firms to Work For Program
- Pittsburgh Practitioner Launches #1 Amazon Bestselling Book Built on Nobel Prize–Winning Science
- Food Journal Magazine Unveils Its Latest 'Best of Los Angeles' Culinary Discoveries
- Boston Industrial Solutions Launches Natron® 717S Series: A New Flexible UV LED Ink for Ricoh GH2220 Printheads
- 5 Things NYC Courier Services Won't Tell You About How Same-Day Delivery Actually Works
- Tropidelic Links Up With International Reggae Star Collie Buddz and Eli Mac for Feel-Good Breakthrough Single "Follow Your Nature"
- Save 15 Percent on Florida Keys Accommodations with KeysCaribbean's 'Advance Purchase Rate Discount'
- Atelier 411 Studios and Columbus Fashion Council Present Red Carpet Experience at Gateway Film Center for The Devil Wears Prada 2
- Inclusive Prom "Garden of Glamour" to Celebrate 150+ Special Needs Guests in Bucks County
- Hazel E Celebrates Birthday with Luxury "Goddess" Yacht Experience in Marina del Rey
- Joseph Neibich sits down with Bold Jounrey (aka Joseph Nybyk)
- AI Suite 360 Launches Done-For-You AI Implementation to Rescue SMBs from the "Frankenstein Tax"
- CX Network Releases Report on the Best AI Support Tools for SaaS Companies 2026